LSE:INDV

Indivior Announces Q1 2024 Financial Results

Retrieved on: 
Thursday, April 25, 2024
Webcast, EST, Indivior

SLOUGH, United Kingdom and RICHMOND, Va., April 25, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024.

Key Points: 
  • SLOUGH, United Kingdom and RICHMOND, Va., April 25, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024.
  • The earnings release, investor presentation and webcast are available at www.indivior.com .
  • There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO.
  • Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BI2351ee9819db40d1a28c31f75cece519

Indivior Announces Q1 2024 Financial Results

Retrieved on: 
Thursday, April 25, 2024
Webcast, EST, Indivior

SLOUGH, United Kingdom and RICHMOND, Va., April 25, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024.

Key Points: 
  • SLOUGH, United Kingdom and RICHMOND, Va., April 25, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024.
  • The earnings release, investor presentation and webcast are available at www.indivior.com .
  • There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO.
  • Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BI2351ee9819db40d1a28c31f75cece519

Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation

Retrieved on: 
Thursday, February 29, 2024
Indivior, Court, Competition law, District court, MDL

RICHMOND, Va., Feb. 29, 2024 /PRNewswire/ -- Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, today announced that its subsidiary, Indivior Inc., has received final Court approval for its settlement with the Direct Purchaser class, concluding the anti-trust multi-district litigation ("MDL") matter.

Key Points: 
  • RICHMOND, Va., Feb. 29, 2024 /PRNewswire/ -- Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, today announced that its subsidiary, Indivior Inc., has received final Court approval for its settlement with the Direct Purchaser class, concluding the anti-trust multi-district litigation ("MDL") matter.
  • On October 22, 2023, Indivior Inc. entered into a settlement agreement with the remaining Direct Purchaser class for $385m.
  • On February 27, 2024, the United States District Court for the Eastern District of Pennsylvania entered an order granting final judgement and order of dismissal approving the Direct Purchaser class settlement and dismissing the Direct Purchaser class claims.
  • This ruling concludes the Antitrust MDL.

Indivior Announces Q4 / FY 2023 Financial Results

Retrieved on: 
Thursday, February 22, 2024
Indivior, EST, Webcast

SLOUGH, United Kingdom and RICHMOND, Va., Feb. 22, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending December 31, 2023.

Key Points: 
  • SLOUGH, United Kingdom and RICHMOND, Va., Feb. 22, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending December 31, 2023.
  • The earnings release, investor presentation and webcast are available at www.indivior.com .
  • There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO.
  • Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BI7bc18cb84a3744af8c4ad20973d37a5a

Indivior Announces Q4 / FY 2023 Financial Results

Retrieved on: 
Thursday, February 22, 2024
Indivior, EST, Webcast

SLOUGH, United Kingdom and RICHMOND, Va., Feb. 22, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending December 31, 2023.

Key Points: 
  • SLOUGH, United Kingdom and RICHMOND, Va., Feb. 22, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending December 31, 2023.
  • The earnings release, investor presentation and webcast are available at www.indivior.com .
  • There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO.
  • Participants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BI7bc18cb84a3744af8c4ad20973d37a5a

Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals

Retrieved on: 
Wednesday, October 11, 2023
LAI, Drug development, Opioid use disorder, Central nervous system, Buprenorphine, Safety, Conditional sentence, OUD, CNS, Justice, Patient, Pharmaceutical industry, Daminozide, Indivior

RICHMOND, Va., Oct. 11, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, today announced that it has gained exclusive global rights to develop, manufacture, and commercialize Alar Pharmaceuticals Inc.'s ("Alar") portfolio of long-acting injectable formulations that release a prodrug1 of buprenorphine at varying durations, including its lead long-acting injectable ("LAI") candidate, ALA-1000.

Key Points: 
  • Under the agreement with Alar, Indivior will pay $10 million to secure exclusive global rights (except in China, Hong Kong, Taiwan and Macau) to develop, manufacture and commercialize ALA-1000 and Alar's future buprenorphine-based LAI product candidates.
  • The $10 million payment is in addition to an initial $5 million option payment made by Indivior to Alar in Q1.
  • Alar is entitled to potential milestone payments if various developmental, regulatory, and commercial goals are achieved.
  • Alar has been granted composition of matter and formulation patents for ALA-1000 covering sustained-release buprenorphine formulations with expiry in 2037 and 2039.

Indivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in Canada

Retrieved on: 
Tuesday, September 26, 2023
Public Health Agency of Canada, COVID-19, Cohort (statistics), Calendar, Opioid use disorder, OUD, Doctor of Philosophy, UDS, Incidence, Addiction medicine, RAAM, Journal, MCFP, Patient, Risk, Injection, Methadone, AM, Journal of Addiction Medicine, Public Health Agency, Fentanyl, Pharmaceutical industry, Indivior

This study, conducted during the COVID-19 pandemic in Canada, also showed improvements in additional parameters suggestive of clinical benefit.

Key Points: 
  • This study, conducted during the COVID-19 pandemic in Canada, also showed improvements in additional parameters suggestive of clinical benefit.
  • The percentage of individuals with urinary drug screen (UDS)-detected fentanyl use within the first month of treatment was 23% with SUBLOCADE; 22% with sublingual buprenorphine/naloxone, and 66% with methadone.
  • During the six months following the initiation of treatment, UDS-detected fentanyl use decreased to 13% with SUBLOCADE, 10% with sublingual buprenorphine/naloxone, and 51% with methadone.
  • "This study shows the potential positive impact of using SUBLOCADE in OUD treatment to help reduce non-fatal opioid overdoses in Canada, including from fentanyl use," said Christian Heidbreder, PhD, Chief Scientific Officer, Indivior.

Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims

Retrieved on: 
Monday, August 21, 2023
Agreement, Ground substance, DSM-IV codes, Trial of the century, MDL, District court, Patient, Nature, Court, News, Insurance, Pharmaceutical industry, Indivior

RICHMOND, Va., Aug. 21, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, announced that its subsidiary, Indivior Inc. (the "Company"), has reached an agreement ("Agreement") to resolve the claims brought by the end payor class of litigants ("the End Payor Claimants") in the In re Suboxone Antitrust Litigation multi-district litigation ("MDL").

Key Points: 
  • RICHMOND, Va., Aug. 21, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, announced that its subsidiary, Indivior Inc. (the "Company"), has reached an agreement ("Agreement") to resolve the claims brought by the end payor class of litigants ("the End Payor Claimants") in the In re Suboxone Antitrust Litigation multi-district litigation ("MDL").
  • The Agreement marks the resolution of the End Payor Claimants' claims against the Company in the MDL.
  • As part of the Agreement, the Company expects to pay $30 million to the End Payor Claimants.
  • Once the Agreement is approved and entered by the Court, the final settlement amount will be recorded against the $188 million provision.

Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims

Retrieved on: 
Monday, August 21, 2023
Agreement, Ground substance, DSM-IV codes, Trial of the century, MDL, District court, Patient, Nature, Court, News, Insurance, Pharmaceutical industry, Indivior

RICHMOND, Va., Aug. 21, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, announced that its subsidiary, Indivior Inc. (the "Company"), has reached an agreement ("Agreement") to resolve the claims brought by the end payor class of litigants ("the End Payor Claimants") in the In re Suboxone Antitrust Litigation multi-district litigation ("MDL").

Key Points: 
  • RICHMOND, Va., Aug. 21, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, announced that its subsidiary, Indivior Inc. (the "Company"), has reached an agreement ("Agreement") to resolve the claims brought by the end payor class of litigants ("the End Payor Claimants") in the In re Suboxone Antitrust Litigation multi-district litigation ("MDL").
  • The Agreement marks the resolution of the End Payor Claimants' claims against the Company in the MDL.
  • As part of the Agreement, the Company expects to pay $30 million to the End Payor Claimants.
  • Once the Agreement is approved and entered by the Court, the final settlement amount will be recorded against the $188 million provision.

Indivior To Participate In Upcoming Investor Conferences

Retrieved on: 
Thursday, May 25, 2023
CFO, LSE, Jefferies, Indivior, Stifel, Conference, Cryptocurrency

Investors can contact their Jefferies representative to schedule a meeting.

Key Points: 
  • Investors can contact their Jefferies representative to schedule a meeting.
  • The presentation will be available at www.indivior.com and can also be viewed using the following webcast link: https://wsw.com/webcast/jeff281/indv.l/2074930
    Stifel European Healthcare Summit – Bordeaux, France, June 29th and 30th
    Mark Crossley, CEO, will participate in the Stifel European Healthcare Conference in Bordeaux, France.
  • Mr. Crossley will host 1x1/group meetings on Thursday, June 29th and Friday, June 30th.
  • Investors can contact their Stifel representative to schedule a meeting.